<DOC>
	<DOCNO>NCT01291745</DOCNO>
	<brief_summary>The present study design determine mutational status marker ( TET2 PLCb2 , cytogenetic aberration ) together methylation status gene use bone marrow match buccal cell sample MDS patient necessitate start treatment ( i.e . EPO , Lenalidomide , Azacytidine ) . All patient include study follow least 2 year .</brief_summary>
	<brief_title>Collection Biological Data With Potential Prognostic Relevance Patients With MYELODYSPLASTIC SYNDROMES</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Written inform consent Patients diagnose MDS accord FAB , WHO IPSS classification All clinically treatable MDS patient EPO Lenalidomide 5Azacytidine ; Hb &lt; 10 g/dL Age â‰¥ 18 year Gender : Male Female Sufficient amount biological sample molecular study Age &lt; 18 year Patients require treatment `` watch wait '' strategy Insufficient amount biological sample molecular study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>